These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6809500)

  • 1. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
    Bergquist C; Nillius SJ; Wide L
    Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
    Bergquist C; Nillius SJ; Wide L; Lindgren A
    Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
    Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
    Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ; Bergquist C; Wide L
    Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
    Gudmundsson JA; Nillius SJ; Bergquist C
    Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
    Gudmundsson JA; Nillius SJ; Bergquist C
    Fertil Steril; 1986 May; 45(5):617-23. PubMed ID: 2938984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovulation inhibition with nafarelin acetate nasal administration for six months.
    Brenner PF; Shoupe D; Mishell DR
    Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
    Nillius SJ; Bergquist C; Wide L
    Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
    Baumann R; Kuhl H; Taubert HD; Sandow J
    Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.
    Nillius SJ
    J Steroid Biochem; 1985 Nov; 23(5B):849-54. PubMed ID: 2934581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
    Lemay A; Jean C; Faure N
    Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
    Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
    J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide contraception in women. Inhibition of ovulation by chronic intranasal LRH agonist therapy.
    Bergquist C; Nillius SJ; Wide L
    Ups J Med Sci; 1984; 89(2):99-106. PubMed ID: 6431676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?
    Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; von der Ohe M; Nevinny-Stickel J
    Contraception; 1981 Feb; 23(2):187-95. PubMed ID: 6786826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial morphology after 6 months of continuous treatment with a new gonadotropin-releasing hormone superagonist for contraception.
    Gudmundsson JA; Lundkvist O; Bergquist C; Lindgren A; Nillius SJ
    Fertil Steril; 1987 Jul; 48(1):52-6. PubMed ID: 2954864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N; Bastide A
    Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent.
    Bergquist C; Nillius SJ; Wide L
    Lancet; 1979 Aug; 2(8136):215-7. PubMed ID: 89330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.